The sector’s most valuable unpartnered assets – up for grabs or on the shelf?
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.